Showing 2771-2780 of 3223 results for "".
- Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbanceshttps://modernod.com/news/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances/2478713/Ocuphire Pharma announced the initiation of patient recruitment and screening in late December for its LYNX-1 phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances (NVD) at multiple sites in the US. NVD, also known as dim light vision disturban
- Moderna Boosts COVID-19 Vaccine Output for 2021 to at Least 600 Million Doseshttps://modernod.com/news/moderna-boosts-covid-19-vaccine-output-for-2021-to-at-least-600-million-doses/2478715/Moderna said it expects to produce a minimum of 600 million doses of its COVID-19 vaccine mRNA-1273 globally this year, up from an earlier estimate of 500 million, and that it is still working to build up to potentially 1 billion doses for 2021. The company also plans to deliver about 100 million
- UK Officials Defend Contingency Plan to Mix COVID-19 Vaccines in Rare Caseshttps://modernod.com/news/uk-officials-defend-contingency-plan-to-mix-covid-19-vaccines-in-rare-cases/2478710/According to a guidance update on December 31, the UK government will allow people to be given doses of different COVID-19 vaccines under certain circumstances, despite a lack of evidence about the extent of immunity offered by such mixing. The issue has sparked criticism after a report in Th
- Haag-Streit UK Announces the Launch of the iVue80 in the UKhttps://modernod.com/news/haag-streit-uk-announce-the-launch-of-the-ivue80-in-the-uk/2478697/Haag-Streit UK has announced the launch of the new iVue80 OCT in the UK. The iVue80 SD-OCT system offers 80,000 A-scans per second—three times faster than the original iVue model—and offers improved efficiency and enhanced image quality. The system also features new scan options and functions, a
- From COVID-19 to Retail Health: Fierce Healthcare’s Biggest Stories of 2020https://modernod.com/news/from-covid-19-to-retail-health-fierce-healthcares-biggest-stories-of-2020/2478689/The year 2020 was dominated by the fallout from a generational global pandemic. So perhaps it’s no surprise that COVID-19 headlines also governed much of
- Sifi Launches Well Fusion Presbyopia Correcting Systemhttps://modernod.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/SIFI announces the launch of the Well Fusion system and the Mini Well Proxa IOL, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. SIFI has develope
- Federal Guidance Enables Employers to Mandate Workers Get COVID-19 Vaccinehttps://modernod.com/news/federal-guidance-enables-employers-to-mandate-workers-get-covid-19-vaccine/2478682/New guidance from the Equal Employment Opportunity Commission allows employers to require workers to get COVID-19 vaccinations, which has major implications for providers, according to a FierceHealthcare
- Kubota Vision Provides Update on Kubota Glasses—Wearable Device for Myopia Controlhttps://modernod.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/Kubota Vision announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology. Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glass
- Bruder Introduces Pre-Surgical Patient Prep Kithttps://modernod.com/news/bruder-introduces-pre-surgical-patient-prep-kit/2478655/Bruder has introduced the Bruder Sx Pre-Surgical Patient Prep Kit, which allow patients’ hygiene products to be available in a single, self-contained kit. Doctors can provide the kit directly in their practices
- GenSight Biologics Announces Publication of Results from Lumevoq REVERSE Pivotal Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-3-trial/2478644/GenSight Biologics announced that the journal Science Translational Medicine has published results from the REVERSE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate stu